Skip to main content

Advertisement

SpringerLink
Log in

Male lower urinary tract symptoms: treatment with α-blockers, 5-α-reductase inhibitors, antimuscarinics, or a combination

  • Published:
Current Urology Reports Aims and scope Submit manuscript

Abstract

Pharmacological therapy is now considered a firstline treatment for men with moderate to severe lower urinary tract symptoms. Given the success of antimuscarinic agents, α-sympathetic blockers, and 5-α-reductase inhibitors in treating symptoms, the interest in combination therapy has grown. Despite this, large-scale trials to test the efficacy of such combination therapy are still lacking.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Chatelain C. Denis L, Foo K, et al.: Recommendations of the international scientific committee. In 5th International Consultation on BPH. Plymouth, UK: Health Publication Ltd.; 2001:519–534.

    Google Scholar 

  2. American Urological Association Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol 2003, 170:530–547.

    Article  Google Scholar 

  3. Roehrborn CG, Boyle P, Nickel JC, et al.: Efficacy and safety of a dual inhibitor of 5-a-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002, 60:434–441.

    Article  PubMed  Google Scholar 

  4. Djavan B, Marberger M: A meta-analysis on the efficacy and tolerability of alpha1-adrenoreceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999, 36:1–13.

    Article  PubMed  CAS  Google Scholar 

  5. Lepor H, Williford WO, Barry MJ, et al.: The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. J Urol 1998, 160:1358–1367.

    Article  PubMed  CAS  Google Scholar 

  6. Kirby RS, Roehrborn C, Boyle P, et al.: Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 2003, 61:119–126.

    Article  PubMed  Google Scholar 

  7. McConnell JD, Roehrborn CG, Bautista OM, et al.: The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003, 349:2387–2398.

    Article  PubMed  CAS  Google Scholar 

  8. Kaplan SA, Walmsley K, Te AE. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 2005, 174:2273–2276.

    Article  PubMed  Google Scholar 

  9. Roehrborn CG, Abrams P, Rovner ES, et al.: Efficacy and tolerability of tolterodine extended release in men with overactive bladder and urgency urinary incontinence. BJU Int 2004, 97:1003–1006.

    Article  Google Scholar 

  10. Kaplan SA, Roehrborn CG, Rovner, ES, et al.: Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder. JAMA 2006, 296:2319–2328.

    Article  PubMed  CAS  Google Scholar 

  11. Gradini B, Realacci M, Ginepri A, et al.: Nitric oxide synthases in normal and benign hyperplastic human prostate: immunohistochemistry and molecular biology. J Pathol 1999, 189:224–229.

    Article  PubMed  CAS  Google Scholar 

  12. Hopps CV, Mulhall JP. Assessment of the impact of sildenafil citrate on lower urinary tract symptoms (LUTS) in men with erectile dysfunction. J Sex Med 2007, In press.

  13. Kaplan SA, Gonzalez RR, Ogiste J, et al.: Combination of an alpha-blocker, alfuzosin SR, and a PDE-5 inhibitor, sildenafil citrate, is superior to monotherapy in treating lower urinary tract symptoms (LUTS) and sexual dysfunction symptoms [abstract 1638]. J Urol 2006, 175:528.

    Article  Google Scholar 

  14. Roehrborn C, McVary K, Kaminetsky J, et al.: The efficacy and safety of tadalafil administered once a day for lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH) [abstract 1636]. J Urol 2006, 175:527.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Baylor College of Medicine, 6560 Fannin Street, Suite 2100, Houston, TX, 77030, USA

    Rodney A. Appell

Authors
  1. Rodney A. Appell
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rodney A. Appell.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Appell, R.A. Male lower urinary tract symptoms: treatment with α-blockers, 5-α-reductase inhibitors, antimuscarinics, or a combination. Curr Urol Rep 8, 370–372 (2007). https://doi.org/10.1007/s11934-007-0033-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11934-007-0033-5

Keywords

Search

Navigation